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Abstract
Background: Chronic neuroinflammation is a hallmark of Parkinson’s disease (PD) pathophysiology, associated with
increased levels of pro-inflammatory factors in PD brain tissues. The pro-inflammatory mediator and highly amyloidogenic
protein S100A9 is involved in the amyloid-neuroinflammatory cascade in Alzheimer’s disease. This is the first report on the
co-aggregation of α-synuclein (α-syn) and S100A9 both in vitro and ex vivo in PD brain.
Methods: Single and sequential immunohistochemistry, immunofluorescence, scanning electron and atomic force (AFM)
microscopies were used to analyze the ex vivo PD brain tissues for S100A9 and α-syn location and aggregation. In vitro
studies revealing S100A9 and α-syn interaction and co-aggregation were conducted by NMR, circular dichroism,
Thioflavin-T fluorescence, AFM, and surface plasmon resonance methods.
Results: Co-localized and co-aggregated S100A9 and α-syn were found in 20% Lewy bodies and 77% neuronal
cells in the substantia nigra; both proteins were also observed in Lewy bodies in PD frontal lobe (Braak stages
4–6). Lewy bodies were characterized by ca. 10–23 μm outer diameter, with S100A9 and α-syn being co-localized
in the same lamellar structures. S100A9 was also detected in neurons and blood vessels of the aged patients
without PD, but in much lesser extent. In vitro S100A9 and α-syn were shown to interact with each other via the
α-syn C-terminus with an apparent dissociation constant of ca. 5 μM. Their co-aggregation occurred significantly
faster and led to formation of larger amyloid aggregates than the self-assembly of individual proteins. S100A9
amyloid oligomers were more toxic than those of α-syn, while co-aggregation of both proteins mitigated the
cytotoxicity of S100A9 oligomers.
Conclusions: We suggest that sustained neuroinflammation promoting the spread of amyloidogenic S100A9 in
the brain tissues may trigger the amyloid cascade involving α-syn and S100A9 and leading to PD, similar to the
effect of S100A9 and Aβ co-aggregation in Alzheimer’s disease. The finding of S100A9 involvement in PD may
open a new avenue for therapeutic interventions targeting S100A9 and preventing its amyloid self-assembly in
affected brain tissues.
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Background
PD is the most common age-dependent neurodegenerative
movement disorder affecting about 2% of the population
over 60 years old. The hallmark of PD is pathological
self-assembly of the amyloidogenic protein α-synuclein
(α-syn), which forms cytotoxic amyloid oligomers and ma-
ture fibrils in PD brain tissues [1, 2]. Native α-syn exists as
an intrinsically disordered monomer. In the presence of
lipid membranes, α-syn undergoes a conformational
change to a folded α-helical secondary structure [3]. Al-
though the biological functions of α-syn are debated, it has
been suggested to play role in maintaining a supply of syn-
aptic vesicles in presynaptic terminals by clustering synap-
tic vesicles, and to be involved in regulating the release of
the neurotransmitter dopamine in controlling voluntary
and involuntary movements [2, 4]. Despite numerous stud-
ies, the critical factors triggering α-syn aberrant conversion
into pathological β-sheet-rich amyloid aggregates and con-
sequently initiation of PD remain unclear. The majority of
PD incidents are sporadic, but inherited α-syn mutations
leading to its amyloid formation at early onset are present
in familial PD, which constitute ca. 10–15% of all PD cases.
When α-syn assembles into amyloid fibrils, these aggre-
gates accumulate in the form of Lewy bodies and Lewy
neurite deposits in neuronal cells primarily in the substan-
tia nigra. These deposits are also found in the frontal lobe,
vagus dorsal motor nuclei, nucleus basalis of Meynert, and
locus coeruleus [5–7]. Amyloid oligomers of α-syn are
considered to be a major cause of neuronal cell toxicity
and progressive neurodegeneration [8]. The latter leads to
PD pathology, which manifests in the loss of motor func-
tion, bradykinesia, rigidity, instability, and tremor. Apart
from the pathogenic neurotoxicity of oligomeric α-syn, the
depletion of α-syn monomers in their physiological loca-
tions due to their aggregation may also contribute to neu-
rodegeneration [3]. An interesting idea of prion-like
transmission of α-syn pathology between neuronal cells
has recently been proposed [9], highlighting that α-syn in
an aberrantly folded, β-sheet-rich conformation can mi-
grate from affected to unaffected neurons, and thus trigger
amyloid templating in the host cells. This indicates that
once aggregation begins, it can effectively spread to the
surrounding tissues, leading to PD progression.
Growing evidence has been accumulated concerning
the importance of additional causal factors that can
contribute to, or turn on, the pathological cascade of
α-syn amyloid aggregation. The most obvious common
denominator in major neurodegenerative diseases, in-
cluding PD and Alzheimer’s disease, is neuroinflamma-
tion [10, 11]. Previously, neuroinflammation was simply
regarded as a response to neurodegeneration in these
diseases. However, recent studies suggest that neuroin-
flammation could be the trigger and the key player in
neurodegenerative diseases by creating a pathogenic
microenvironment in the brain tissues. PD brains
showed extensive microglial activation, infiltration of
blood-derived mononuclear phagocytes and lymphocytes,
and significant rise of pro-inflammatory cytokines—all
deleterious responses, which can sustain inflammation
and exacerbate neurodegeneration [11–13]. Moreover,
epidemiological studies have demonstrated that nonsteroi-
dal anti-inflammatory drugs may lower the risk of neuro-
degenerative diseases, including both Alzheimer’s disease
and PD [12, 14].
The importance of co-aggregation of amyloidogenic
proteins in a number of neurodegenerative diseases
has recently been highlighted [15]. It has been shown
that molecules designed to inhibit aggregation of one
amyloidogenic protein may inhibit the aggregation of
others [16, 17] and thus potentially affect the whole
amyloid cascade.
In this study, we have focused on the involvement in
PD pathology of the specific pro-inflammatory mediator
S100A9, which we have found to play a critical role in
connecting neuroinflammatory and amyloid pathologies
into the integrated amyloid-neuroinflammatory cascade
in Alzheimer’s disease [18]. S100A9 belongs to the
family of structurally homologous calcium-binding S100
proteins, which are broadly involved in many inflamma-
tory, cancer, and neurodegenerative conditions [19]. We
have previously shown that S100A9 is highly amyloido-
genic and easily forms amyloid oligomers and fibrils
under in vitro conditions that mimic physiological
conditions [18, 20]. In Alzheimer’s disease, S100A9 was
found to be abundant both in neuronal cells and in amyl-
oid plaques, prompting co-aggregation with amyloid-β
(Aβ), the major amyloidogenic peptide in Alzheimer’s
disease [18]. It has therefore been suggested that
pro-inflammatory S100A9, which possesses intrinsic amy-
loidogenic properties as well as the ability to modulate Aβ
aggregation, can serve as a link between the Alzheimer’s
disease amyloid and neuroinflammatory cascades and as a
prospective therapeutic target [18]. Interestingly, the crit-
ical role of S100A9 in Alzheimer’s disease development
was demonstrated in a mouse model, where S100A9 pro-
duction was induced by both the Aβ peptide and the
C-terminal fragment of the Aβ precursor protein, while
S100A9 knockdown attenuated memory impairment and
reduced amyloid plaque burden [21]. Among the brain
pathologies, a widespread expression of S100A9 has been
reported in cerebral malaria [22], cerebral ischemia [23],
Alzheimer’s disease [18, 24], and traumatic brain injury
[25], where it may initiate sustainable inflammatory
responses and perform mediator functions controlling
inflammatory responses of other cells. An abundance of
S100A9 mRNA has recently been identified as a strong
feature of aging in various mammalian tissues, including
the central nervous system, and a novel mechanism of
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age-associated inflammation sustained by S100A9 has
been suggested [26].
The role of S100A9 in PD remains to be elucidated.
There are clear indications that another protein from
the S100 protein family—S100B—plays a role in PD [27,
28]. Elevated S100B levels were found in the postmor-
tem substantia nigra of PD patients compared with con-
trol tissues, and S100B levels in the cerebrospinal fluid
were also higher in a large cohort of PD patients com-
pared with controls [27]. Autoimmune responses to
S100B in the blood sera of PD patients were also signifi-
cantly higher than in control subjects [28]. Moreover,
transgenic mice overexpressing S100B developed PD fea-
tures, resulting in motor coordination impairment [29].
Here, by using combined analysis of ex vivo PD-affected
brain tissues and S100A9 co-aggregation with α-syn in
vitro, we show that S100A9 indeed complements
α-syn amyloid aggregation and is involved in the
amyloid-neuroinflammatory cascade in PD pathology.
Methods
Proteins
S100A9 (13.2 kDa, 114 amino acid residues) and α-syn
(14.4 kDa, 140 residues) were expressed and purified from
E. coli as described previously [30, 31]. Proteins were
freeze-dried and used directly after dissolving them in
phosphate buffered saline (PBS, 09-8912-100, Medicago).
All samples were passed through a 0.22-μm filter to elim-
inate spontaneously formed aggregates. 15N-labeled α-syn
was purchased from AlexoTech AB. Protein concentra-
tions were determined by absorption at 280 nm with ex-
tinction coefficients of ε280 = 0.53 (mg/mL)
−1 cm−1 for
S100A9 and 0.41 (mg/mL)−1 cm−1 for α-synuclein,
respectively.
Tissue samples
The postmortem brain tissues from five PD patients and
four controls were examined (Table 1). Controls had no
neurodegenerative diseases, in particular no Lewy bodies
or neurofibrillary tangles or anything else indicative of a
neurodegenerative condition in the substantia nigra or
frontal lobe as confirmed by the neuropathologist collab-
orator at the Institute of Neurology, Medical University of
Vienna, Vienna, Austria, who provided the tissue samples
for analysis. All tissue sections were from the frontal lobe
and midbrain regions. They were paraffin-embedded and
microtome-sectioned to 5-μm-thick slices.
Immunohistochemistry
Single and sequential immunohistochemistry with a series
of antibodies applied to the same tissue sections were per-
formed as described previously [32] with some modifica-
tions [33]. The following primary antibodies from Santa
Cruz Biotechnology were used: S100A9 (rabbit polyclonal,
sc-20173, 1 in 100), α-syn (mouse monoclonal, 3G282:
sc-69977, 1 in 100, raised against recombinant α-syn of
human origin), and CD68 (mouse monoclonal, sc70761, 1
in 100). In some control experiments, α-syn mouse mono-
clonal, LB 509 (Novakemi AB), was also used, raised
against Lewy bodies purified from patients suffering de-
mentia with Lewy bodies, and reactive with α-syn epi-
tope located in the region of amino acids 115-122.
Both α-syn antibodies showed consistent immuno-
staining. Secondary antibodies from Vector Laborator-
ies were used: anti-mouse (MP-7402) and anti-rabbit
(MP-7401) IgG peroxidase reagent kits. 3,3′-Diamino-
benzidine (DAB) and 3-amino-9-ethylcarbazole (AEC)
from Vector Laboratories were used as substrates pro-
ducing brown and reddish-brown staining of the sam-
ples, respectively. The tissues were scanned by a
Panoramic SCAN slide scanner 250 (3D Histech).
Quantifications of S100A9-immunopositive cells in
the substantia nigra and frontal lobe areas of five PD
patients and four controls were conducted by selecting
six random areas of 1 × 1 mm2 size in each tissue sec-
tion and calculating the mean value over all counts.
The percentage of co-localization of S100A9 and α-syn
within cells in the substantia nigra was counted relative to
α-syn-immunopositive cells. Lewy bodies were counted in
the whole substantia nigra and frontal lobe regions of five
PD patients, and co-localization of S100A9 and α-syn was
calculated relative to α-syn-immunopositive inclusions.
Immunofluorescence
The brain tissues were cut into 5-μm-thick sections, depar-
affinized in xylene, rehydrated in a graded series of alcohol,
followed by antigen retrieval in citrate buffer, pH 6.0, and
washed in Tris-buffered saline Tween. The tissue sections
were blocked with 5% bovine serum albumin (BSA) in PBS
for 30 min at 37 °C, and then incubated during 1 h with
primary antibodies diluted in 2.5% BSA. The following pri-
mary antibodies from Santa Cruz Biotechnology were used:
α-syn (mouse monoclonal, sc-69977, 1 in 200) and S100A9
Table 1 Characteristics of PD and control subjects, including
age, gender, and stage of PD [49]
Age Gender Stage
PD patients 83 Female Braak 5
69 Male Braak 5
83 Male Braak 5
82 Male Braak 6
75 Male Braak 4
Control patients 83 Female –
69 Male –
83 Male –
75 Male –
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(rabbit polyclonal, sc-20173, 1 in 200). Then, the tissue
samples were washed twice in PBS and incubated with
Alexa Fluor 555 goat anti-mouse IgG secondary antibodies
(10 μg/mL, A28180, Thermo Fisher Scientific), interacting
with α-syn-specific primary antibodies, and observed by
orange fluorescence and with Alexa Fluor 488 goat
anti-rabbit IgG secondary antibodies (10 μg/mL, A-11034,
Thermo Fisher Scientific), interacting with S100A9-specific
primary antibodies, and observed by green fluorescence.
The secondary antibodies were diluted in 2.5% mouse and
rabbit serum, respectively; they were applied for 30 min at
room temperature. Cell nuclei were stained with 4′,6-Dia-
midine-2′-phenylindole dihydrochloride (DAPI, Roche).
Fluorescence microscopy was conducted on an Axio
Imager A1 microscope (Carl Zeiss).
Congo red staining
Deparaffinized and rehydrated tissue sections of 5 μm
thickness were stained with a saturated ethanol solution
of Congo red (Sigma) and sodium chloride and taken to
pH 10.0 with 1% sodium hydroxide. Cell nuclei were
stained with hematoxylin (Vector Laboratories). The
stained samples were examined in an optical microscope
(Leica DM LB).
Amyloid formation kinetics
To produce amyloid aggregates, S100A9 and α-syn pro-
teins were incubated in PBS, pH 7.4 and 37 °C. The
amyloid formation kinetics was monitored as described
previously [20]. To monitor amyloid formation kinetics,
20 μM thioflavin T (ThT) was initially added to native
protein samples. The samples were placed in 96-well
non-binding black plates (Corning), subjected to agita-
tion at 300 rpm, and ThT fluorescence intensity was
monitored by a Tecan Infinite F200 plate reader.
S100A9 and α-syn were cross-seeded with 5 and 10%
of pre-formed amyloids of their counter-parts (molar
percentage). The α-syn/S100A9 amyloid cross-seeding
experiments were performed at the above conditions
under 200 rpm agitation and their ThT fluorescence was re-
corded by a Fluostar Optima (BMG Labtech) plate reader.
Fluorescence excitation wave length was set at 440 nm, and
emission was registered at 480 nm every 10 min. Each
sample was measured at least in eight replicates.
Amyloid kinetic fitting
Fitting of the amyloid kinetic curves was performed by
using a sigmoidal function described in [34]
I tð Þ ¼ Imin þ Imax
1þ e−t−t0τ
; ð1Þ
where I(t) is normalized fluorescence intensity, Imin—
fluorescence intensity at time 0, Imax—fluorescence
intensity at the plateau level, t0—midpoint of the growth
phase (inflection point), τ—characteristic reaction time
equal to 1/Kapp, where Kapp is an apparent reaction rate
constant. Lag-phase time is defined as tlag = t0−2τ.
Fitting was conducted by using a Wolfram Mathematica
11 package. Each experimental amyloid formation kin-
etic curve is an average of five repeats, and each repeat
was fitted by Eq. (1). The rates derived from all repeats
were subjected to statistical analysis to determine if the
difference between the group rates is statistically signifi-
cant. Level of statistical significance was set at 0.05.
AFM
AFM imaging of the protein fibrils and tissue samples
was carried out by a BioScope Catalyst AFM (Bruker) in
peak force mode in air, with resolution of 512 × 512
pixels. ScanAsyst air cantilevers (Bruker) were used. Pro-
tein samples were diluted 50 times in deionized water
and incubated on the surface of freshly cleaved mica for
15 min, washed three times with 100 μl deionized water,
and dried at room temperature. Instrumental set up in-
cluding a BioScope Catalyst AFM combined with an
inverted Nicon-Ti-S microscope equipped with tissue
slide holder was used for combining the immunohisto-
chemical staining pattern with AFM imaging in analysis
of Lewy bodies in the substantia nigra brain tissues.
Lewy body dimensions
Lewy body dimensions from a single patient were mea-
sured by using AFM topographic imaging, which provides
higher accuracy compared to immunohistochemical stain-
ing. The measurements were performed in the AFM
cross-sections of topographic images as shown in Fig. 1i.
The estimates of outer and inner diameters of Lewy body
toroidal structures are shown by red lines, drawn through
the inflection points in their cross-sections, which were
determined by first derivatives of the corresponding
cross-section profiles.
Scanning electron microscopy
Scanning electron microscopy of the brain tissue sam-
ples was performed by a Carl Zeiss Merlin field emission
scanning electron microscope using accelerating voltage
of 4 kV. Prior to imaging process, the tissue slide was
coated with carbon in a Quorum Q150T-ES specimen
preparation station.
Cellular toxicity
SH-SY5Y neuroblastoma cells were cultured as de-
scribed previously [35]. Cells were plated at a density of
ca. 100 cells/well in 96-well plates; the medium was
changed after 24 h of incubation and before adding pro-
tein samples. Initially, S100A9 and α-syn were incubated
at concentrations of 70 μM in PBS, pH 7.4, and 37 °C
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during 10 and 60 h in order to produce the amyloid
samples populated with oligomers/protofilaments and fi-
brils, respectively. The time points of sample collection
were selected in accord with the kinetics of amyloid for-
mation and AFM imaging for all protein specimens.
Freshly dissolved and pre-incubated amyloid samples of
S100A9, α-syn, and their mixture were diluted in the
culture medium and added to SH-SY5Y cells at a final
concentration of 10 μM. Cell viability was measured by
WST-1 assay (Roche) after 24 h of co-incubation with
added protein samples. Absorbance at 450 nm was mea-
sured in a plate reader (Tecan Infinite F200). Cell
Fig. 1 Microscopy of α-syn Lewy bodies in the PD substantia nigra (an individual case). a–c Representative intracellular Lewy bodies immunostained
with α-syn antibodies. Lewy bodies are shown in dark brown color and the host cells in lighter brown shade. Scale bars equal to 10 μm. d–f AFM
height images of the corresponding Lewy bodies (from a–c). The surfaces of Lewy bodies and surrounding tissues are covered with DAB crystals used
in immunohistochemical procedure to stain the tissue samples (shown in light color). Image sizes are 20 × 20 μm. g, h Scanning electron microscopy
images of Lewy bodies shown in a, b. i AFM cross-section of Lewy body; its position is shown in f by white line. j, k Distribution of Lewy body mean
outer and inner diameters, respectively, calculated by using BCa technique from AFM data. Mean diameters and their 95% CI are shown above the
histograms. Probability density function (PDF) is shown along the y-axis. l Linear dependence between the inner and outer diameters of the Lewy
bodies analyzed by AFM. Each point represents individual randomly selected Lewy body from the same patient and is shown in individual color
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viability was expressed as a percentage of the absorbance
in wells containing control cells with added PBS. All ex-
periments were performed at least in triplicates, and
each series was repeated three times. The amyloid sam-
ples were incubated in sterile conditions prior to adding
to the cell culture media.
Circular dichroism (CD)
Far UV CD spectra of both S100A9 and α-syn were re-
corded in 10 mM phosphate buffer, pH 7.4, and 20 °C
with a Jasco J-710 spectropolarimeter using a 1-mm path
length quartz cuvette.
NMR spectroscopy
A Bruker Avance 700 MHz NMR spectrometer equipped
with a triple-resonance cryoprobe was used to perform
NMR measurements. 2D 1H,15N heteronuclear single
quantum coherence (HSQC) spectra of 77 μM
isotope-labeled α-syn in 10 mM phosphate buffer,
pH 7.35, and 10 °C were recorded before and after
addition of 2.5 mM S100A9. The spectra were refer-
enced to the water signal, and the assignment of
α-syn amide cross-peaks was used from previous
work [36].
Surface plasmon resonance
The interaction between α-syn and S100A9 were exam-
ined by using a Biacore X100 surface plasmon resonance
instrument (GE Healthcare). Monomeric α-syn was
immobilized on a streptavidin-coated chip as described
previously [37]. The binding was measured in HBS-P+
buffer containing 10 mM HEPES, 150 mM NaCl, and
0.001% P20 detergent at pH 7.4 (GE Healthcare) and 25 °
C. Increasing concentrations of S100A9 were injected in a
single cycle sequence without regeneration steps between
injections. At the end of the cycle, bound protein was
removed by injection of 50 mM NaOH. Experiments were
repeated three times. Dissociation constant Kd was evalu-
ated with the program provided by the instrument manu-
facturer using the equation: Rc = (C*Rmax)/(Kd +C), where
Rc denotes binding level at concentration C and Rmax is
the extrapolated maximum binding capacity.
Statistical analysis
The normality of all data sets was assessed by the
Shapiro-Wilk test. Values of p ≤ 0.05 were considered
statistically significant. The experimental data sets were
normally distributed and therefore analyzed by using
two-sample T test. These results are shown as mean ±
standard deviation (SD).
The means of outer and inner diameters of Lewy bod-
ies (13 bodies) and their 95% confidence intervals (CI
95%) were calculated by corrected and accelerated boot-
strap (BCa) technique [38, 39].
Results
S100A9 and α-syn in Lewy bodies in the PD substantia
nigra and frontal lobe regions
The tissue samples from five PD patients and four con-
trol individuals (Table 1) were subjected to immunohis-
tochemical analysis to examine the localization of α-syn
and S100A9 antigens. Since Lewy body formation in the
substantia nigra is a hallmark of PD pathology [40], we
have examined the prevalence of intracytoplasmic Lewy
bodies reactive with α-syn antibodies in the substantia
nigra of five PD patients. A large number of Lewy bodies
distributed all over the substantia nigra were detected in
all PD patients, and in one representative patient, they
were studied in more detail by combining immunohisto-
chemistry and AFM imaging. Lewy bodies were strongly
immunoreactive with α-syn antibodies as shown in the
representative images in Fig. 1a–c, displaying character-
istic pattern with a bright ring-shaped staining around
the pale central core. Most Lewy bodies were located
within neuronal cells shown in lighter brown shade at
their background. Some neuronal cells contained two
Lewy bodies (Fig. 1b, c), which is typical for PD path-
ology. This indicates that once the process of amyloid
self-assembly has started within a cell, the developed
amyloids can seed and propagate themselves.
The topographic AFM images of the same Lewy bod-
ies in the substantia nigra tissues are shown in Fig. 1d–f,
the images were scanned by positioning the AFM canti-
lever over the optical images of corresponding Lewy
bodies. Since the Lewy bodies were initially localized
within the brain sections by immunostaining, the sur-
faces of their sections were covered by DAB crystals
used in immunohistochemical procedure. These surfaces
are higher and displayed in a light color in AFM images,
while the central parts not reactive with α-syn antibodies
are shown in darker color, respectively (Fig. 1d–f ). It
was suggested that a granular core of Lewy bodies may
include a variety of nitrated, phosphorylated, and ubiqui-
tinated proteins surrounded by a filamentous halo con-
taining α-syn amyloid fibrils [40]. The same individual
Lewy bodies were imaged also by using scanning elec-
tron microscopy as shown in Fig. 1g, h, where they dis-
play the same morphology. Since the immunopositive
parts of Lewy bodies are visible as annuli, we measured
their outer and inner diameters in the AFM
cross-sections (Fig. 1f, i). By using corrected and acceler-
ated bootstrap technique, we calculated the probability
density functions for means of both Lewy body diame-
ters and their respective 95% confidence intervals (Fig. 1j,
k). The mean value for outer diameters of all examined
Lewy bodies was 14.7 μm (CI 95% 13.0–16.7) and for
the inner diameters 7.9 μm (CI 95% 8.5–10.4), respect-
ively. The dependence between the outer and inner di-
ameters of Lewy bodies is linear with a slope of 0.99,
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indicating that the thickness of the annuli is propor-
tional to their diameters (Fig. 1l). The diameters of Lewy
bodies were also measured by using scanning electron
microscopy images (Fig. 1g, h), which resulted in the di-
mensions consistent with AFM measurements.
The substantia nigra tissue sections from five PD patients
were also subjected to the sequential immunohistochemis-
try with pair of consecutively applied S100A9 and α-syn
antibodies, which revealed that some intracytoplasmic
Lewy bodies were clearly immunoreactive with both anti-
bodies as shown in two pairs of representative images
(Fig. 2a–d). The host cells, containing these Lewy bodies,
displayed typical neuronal morphology (Fig. 2a–d). Both
immunostaining patterns were overlapping, demonstrating
the obvious co-localization of both S100A9 and α-syn
within Lewy bodies. Particularly strong co-immunostaining,
reflecting co-localization of these two antigens, was ob-
served at the outer layer region, shown as a bright ring
(Fig. 2c, d), though some Lewy bodies were more uniformly
stained in the whole section (Fig. 2a, b). The Lewy bodies
were also reactive with Congo red dye binding specifically
to amyloid inclusions as shown in Fig. 2e. The Lewy bodies
in the substantia nigra were also observed by using
immunofluorescence, i.e., intracellular Lewy body inclu-
sions reactive with α-syn antibodies were recognized by
orange fluorescence (Fig. 2f). Some small inclusions dis-
played green fluorescence characteristic for S100A9-specific
antibodies or yellow color, indicating the overlap of orange
and green fluorescence and co-localization of both antigens
(Fig. 2f). The Lewy bodies immunoreactive with α-syn
antibodies were counted across all substantia nigra region
in all five PD patients and their amounts were within
300–350 per case. Lewy body inclusions immunoreactive
with either α-syn or S100A9 antibodies were not observed
in the substantia nigra and frontal lobe tissues of control
individuals (Fig. 3). We have found that ca. 20% of
α-syn-immunopositive Lewy bodies in the substantia nigra
were also immunopositive with S100A9 antibodies (Fig. 4l),
indicating that S100A9 together with α-syn contributes to
Lewy body formation. In some neuronal cells in the
substantia nigra, small granular structures immunopositive
with both S100A9 and α-syn antibodies were also ob-
served (as indicated by black arrows in Fig. 4e, g), suggest-
ing initiation of PD pathology and potential Lewy body
development.
Lewy body inclusions were found also in the frontal
lobe areas of all five PD patients by using both immuno-
histochemistry and immunofluorescence (Fig. 2g–j).
They were observed as round-shaped inclusions reactive
with α-syn antibodies as shown by immunohistochemis-
try (Fig. 2g) or orange spheres as shown by immuno-
fluorescence (Fig. 2j). Some inclusions were rather large
but irregular in shape (Fig. 2h). In some neurons, the
granular structures displaying orange, green, or yellow
fluorescence were noticed, indicating the deposition of
α-syn, S100A9, or their co-localization, characteristic for
the initiation of amyloid pathology (Fig. 2i, j). The
numbers of Lewy bodies in the PD frontal lobe areas
were within a wider range of 80 to 240 per case (versus
300–350 per case in the substantia nigra) and up to 16
times lower per square millimeter of the tissue than in the
substantia nigra. In the frontal lobe, co-immunostaining
of the Lewy bodies with α-syn and S100A9 antibodies was
observed in ca. 20% cases, similar to the substantia nigra.
Neuronal S100A9 in the PD substantia nigra and frontal
lobe regions
The brain tissues of five PD patients compared to four
controls were also examined for the intracellular presence
of both α-syn and S100A9 antigens, which may precede
the aggregation and Lewy body formation. Both proteins
are known to be expressed in neuronal cells, and the
elevated levels of S100A9 have been reported in Alzhei-
mer’s disease and aging [18, 24, 26]; however, no informa-
tion is available for PD-affected brain tissues. Specifically,
the tissue sections from the PD-affected midbrain and
frontal lobe areas have been analyzed, since both these
areas were reported to be dysfunctional in PD [41].
Numerous brightly stained S100A9-immunopositive cells
with a characteristic neuronal morphology were observed
both in the substantia nigra and in the frontal lobe areas
(Fig. 4a, e, i). Some of the neurons in the substantia nigra
contain also neuromelanin, which was reflected in their
characteristic brown color compared to the
antigen-specific reddish-brown staining (Fig. 4f, g).
Sequential immunohistochemistry with antibodies to
S100A9, α-syn, and CD68 (specific for activated microglial
cells and macrophages) was performed to examine if
S100A9 and α-syn are produced also by microglial cells in
the substantia nigra and two representative immunostain-
ing sequences are presented in Fig. 4a–d and Fig. 4e–h,
respectively. The overlap of individual immunostaining
patterns for S100A9 and α-syn in the arbitrary colors
indicates the co-localization of these proteins in neuronal
cells. The co-localization of the S100A9/α-syn and CD68
immunostaining patterns in the substantia nigra was at
the level of immunohistochemical detection, indicating
that S100A9 is accumulated primarily in neurons
(Fig. 4d, h), though we cannot exclude its presence in
microglial cells. In the substantia nigra, α-syn, but not
S100A9, was also accumulated in Lewy neurites
(Figs. 2b and 4c), which is a pathological hallmark of
PD. Substantial amount of S100A9-immunopositive
neurons were observed in the frontal lobe area of all
five PD patients, as shown in representative image in
Fig. 4i, and some neuronal cells were α-syn positive as
shown by immunofluorescence (Fig. 2i, j). The sequen-
tial immunohistochemistry with S100A9 (Fig. 4i) and
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Fig. 2 (See legend on next page.)
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CD68 (Fig. 4j) antibodies, followed by the superposition
of immunostaining patterns in the arbitrary colors
(Fig. 4k), indicated that there is no co-localization of
the staining patterns and therefore no detectable
S100A9 in microglial cells in the frontal lobe tissues.
In the tissue samples from both the substantia nigra and
frontal lobe of all four control individuals, intra-neuronal
staining with α-syn antibodies was also observed shown in
reddish-brown color (Fig. 3a, b), while brown coloring in
the substantia nigra neurons corresponded to neuromela-
nin. However, the amount of cells immunoreactive with
α-syn antibodies was much lower in the controls than in
the PD patients. Since the α-syn antibody used in the
study detects also the physiological form of α-syn and not
selective for the disease-associated conformation, we
interpret the occasional cytoplasmic staining as physio-
logical expression of α-syn in neurons. This is clearly
different from the inclusion-body pathology (i.e., Lewy
bodies) seen in the PD samples.
In both brain regions of all four control individuals,
the blood vessels were immunopositive for S100A9 anti-
bodies as shown in the representative staining in Fig. 3d,
indicating that S100A9 is produced there by myeloid
cells. Some S100A9-immunopositive cells were also ob-
served, but to a much lesser extent than in PD patient
tissues (Fig. 3c, d).
The amounts of S100A9-immunopositive cells were
counted in randomly selected areas of the substantia nigra
and frontal lobe in each patient and averaged over all PD
and control cases, respectively (Fig. 4l). Importantly, these
(See figure on previous page.)
Fig. 2 Optical and fluorescence microscopy of Lewy bodies in the substantia nigra and frontal lobe regions of five PD patients. Representative
sequential immunohistochemistry of Lewy bodies formed in neuronal cells in the PD substantia nigra tissues and conducted by using the pair
of consecutive S100A9 (a, c) and α-syn (b, d) antibodies, respectively. e Congo red staining of intracellular Lewy body in the substantia nigra.
f Immunofluorescence of the representative substantia nigra tissue with α-syn antibodies (shown in orange), S100A9 antibodies (in green), their
superposition (in yellow), and DAPI staining of cell nuclei (in blue). The Lewy body in the center of image is shown as a well-defined round-shaped
intracellular inclusion. The Lewy body in the lower right corner is shown in yellow indicating staining with both S100A9 and α-syn antibodies. g, h
Immunohistochemistry of the representative frontal lobe tissues with α-syn antibodies. i, j Immunofluorescence of the representative frontal lobe
tissues with α-syn and S100A9 antibodies and DAPI staining. Color representation as in f. In the images, the labelling notes for S100A9 and α-syn
antibody staining is shown in green and orange, respectively. Scale bars are 50 μm in a–d, g, and h, 20 μm in e, f, and 100 μm in i, j
a b
c d
Fig. 3 Immunohistochemical analysis of the brain tissues of four control cases. Representative immunostaining with α-syn (a, b) and S100A9 (c, d)
antibodies of the substantia nigra (a, c) and frontal lobe (b, d) tissues, respectively. Neuromelanin is shown in brown color and immunostaining with
corresponding antibody in reddish color. Scale bars are 100 μm
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numbers significantly increased in PD patients compared
to controls both in the substantia nigra and frontal lobe,
i.e., by ca. sixfold. Sequential immunohistochemistry with
S100A9 and α-syn antibodies revealed that 77% of the
neuronal cells immunopositive with α-syn antibodies in
the substantia nigra were also immunopositive with
S100A9 antibodies, indicating the co-localization of both
antigens (Fig. 4l).
Amyloid aggregation of α-syn and S100A9
The amyloid formation kinetics of α-syn, S100A9, and
their equimolar mixture, incubated under continuous
agitation in PBS, pH 7.4 and 37 °C, were monitored by
ThT fluorescence assay, since ThT fluorescence increases
when the dye binds specifically to amyloid structures
(Fig. 5a). The S100A9 fibrillation was characterized by a
shorter lag phase compared to the α-syn amyloid assem-
bly, i.e., ca. 9 vs 16 h, respectively (Fig. 5a, b). The
growth phase of S100A9 fibrillation was slower than the
α-syn amyloid growth with the midpoints at 36 vs 31 h,
respectively (Fig. 5b). However, when both proteins were
mixed at equimolar ratio, the lag phase of their joint
amyloid aggregation became equal to that of S100A9
alone, while the midpoint of the growth phase reduced
to ca. 16 h (Fig. 5b). The described differences in the lag
times and midpoints for α-syn amyloid kinetics in the
a b c d
e
i j k l
f g h
Fig. 4 Immunohistochemical analysis of neuronal S100A9 in the PD substantia nigra and frontal lobe tissues (five cases studied). a–c Sequential
immunohistochemistry of the representative PD substantia nigra region with S100A9, CD68, and α-syn antibodies, respectively. d Superposition of the
corresponding images from a–c shown in pseudo-colors: S100A9 immunostaining is shown in yellow, α-syn in blue, and CD68 in magenta. e–g Enlarged
images of the sequential immunohistochemistry of the representative substantia nigra region collected from another PD patient and conducted by using
S100A9, CD68, and α-syn antibodies, respectively. Black arrows mark the accumulation of α-syn and S100A9 in small granules. h Superposition of the
corresponding images from e–g shown in pseudo-colors: color coding as in d. i, j Sequential immunohistochemistry of the representative PD frontal lobe
tissues with S100A9 and CD68 antibodies, respectively. k Superposition of the corresponding images from i, j shown in pseudo-colors: color coding as in
d. l Counts of S100A9-immunopositive neuronal cells in controls are shown by black bars and in PD patients by red bars; frontal lobe is labeled by FL and
substantia nigra by SN. Percentage of the co-localization of S100A9 and α-syn within neuronal cells and Lewy bodies in the substantia nigra shown by
blue bars. p≤ 0.05 is indicated by *. Scale bars are 100 μm in a–d and 50 μm in e–k
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presence and absence of S100A9 were statistically sig-
nificant. In addition, the growth rate constant for α-syn
mixed with S100A9 was by ca. 40% faster than that of
α-syn alone (Fig. 5c). The amyloid formation of α-syn
was also observed in the presence of 5 and 10% S100A9
sample with preformed fibrils, characterized by smaller
shift of the lag phase, growth midpoint, and apparent rate
constants to lower values compared to the fibrillation of
α-syn alone (Additional file 1). However, no deviations
from the original fibrillation curve of S100A9 (Fig. 5a)
were observed in the presence of 5 and 10% of α-syn pre-
formed fibrils. These indicate that native S100A9, rather
than its fibrils, can potentiate α-syn amyloid formation.
The amyloid formation of both proteins was moni-
tored also by AFM imaging (Fig. 5d–i). After 10 h incu-
bation, both S100A9 and α-syn developed round-shaped
oligomers with ca. 3–4 nm and 5–6 nm heights in AFM
cross-sections, respectively (Fig. 5d, e). After the same
incubation time of the equimolar mixture of both pro-
teins, the elongated protofilaments were developed coex-
isting together with oligomers of ca. 3–10 nm heights
(Fig. 5f ). After 60 h incubation, S100A9 self-assembled
into curly fibrils with ca. 4 nm heights in the AFM
cross-section (Fig. 5g, j), while α-syn formed mature
fibrils of a few micron lengths and 8–10 nm heights in
AFM cross-sections (Fig. 5h, k). Interestingly, the
co-incubation for 60 h of their equimolar mixture resulted
in the formation of large clustered aggregates coexisting
with smaller curly and round-shaped structures (Fig. 5i).
Cytotoxicity of S100A9 and α-syn amyloids
The cytotoxic effect on SH-SY5Y neuroblastoma cells
produced by the native and amyloid species of S100A9,
α-syn, and their equimolar mixture was assessed by
using a WST 1 assay (Fig. 5l; statistical analysis is shown
in Additional file 2). Freshly dissolved S100A9 and its
mixture with α-syn added to SH-SY5Y cells caused
reduction of cell viability by ca. 23 and 18%, respectively,
compared to control with added PBS, while freshly
dissolved α-syn did not induce statistically significant
cytotoxic effect. The amyloid species of both α-syn,
S100A9, and their mixture formed after 10 h incubation
appeared to be the most cell toxic, causing the reduction
of cell viability by ca. 40, 70, and 45%, respectively; the
difference between the cytotoxicity induced by α-syn
and 1:1 mixed oligomeric samples was not statistically
significant. These samples were collected during the lag
phase of the amyloid formation kinetics of α-syn and in
the beginning of growth phase of the amyloid kinetics of
S100A9 and 1:1 mixture as shown in Fig. 5a by green
arrow. Therefore, the predominant amyloid species in
these samples were oligomers in the α-syn and S100A9
samples and oligomers together with short protofila-
ments in the sample of mixed proteins as shown in the
AFM images in Fig. 5d–f. Amyloid fibrils of each protein
and their mixture were collected after 60 h incubation,
i.e., their time point of collection is indicated by red
arrow in the amyloid kinetic curves (Fig. 5a) and the
amyloid structures developed in each sample during this
period of time are shown in the AFM images (Fig. 5g–i).
The mature amyloid fibrils of α-syn, which are shown as
micron length polymers in Fig. 5h, became significantly
less toxic compared to all three oligomeric samples, re-
ducing cell viability to the level indistinguishable from
control (Fig. 5l). The amyloid fibrils of mixed proteins
also became significantly less toxic than S100A9 oligo-
mers, reducing cell viability by ca. 30% compared to
control. However, the change in cellular toxicity of short
amyloid fibrils of S100A9 was statistically insignificant
compared to those of all three oligomeric species (Fig. 5l,
Additional file 2).
Interactions of native S100A9 and α-syn
The interactions of native S100A9 and α-syn were
analyzed by using solution NMR, CD spectroscopy, and
surface plasmon resonance. 2D 1H,15N-HSQC spectra of
77 μM α-syn were recorded before and after addition of
S100A9 performed in titration steps with up to 2.5 mM
final concentration, to ensure the binding site saturation
(Fig. 6a). The 2D 1H,15N-HSQC spectrum of free α-syn
closely resembles previously assigned spectra of this pro-
tein under similar conditions [36], thus confirming that
it exists in an essentially unstructured conformation,
characterized by transiently populated α-helices in the
N-terminal and central regions, but with the last 40
residues of the C-terminus being more unfolded and
extended. Addition of S100A9 did not significantly
perturb the positions of α-syn HSQC amide cross-peaks
(Fig. 6a), but their intensities generally decreased to ca.
80% compared to the original values. Interestingly, the
decrease was more pronounced in the C-terminus, i.e.,
to ca. 70%, suggesting a possible binding site for S100A9
in the C-terminal part of monomeric α-syn (Fig. 6b).
The CD spectrum of α-syn in the far UV region also
confirmed its largely unstructured conformation, display-
ing the minimum of ellipticity at ca. 197 nm typical for
random coil (Fig. 6c). The CD spectrum of native S100A9
is dominated by a signal corresponding to an α-helical
conformation with characteristic strong minima at 220
and 208 nm (Fig. 6c). Since the α-helical structure of
S100A9 is very stable, while the unfolded conformation of
α-syn can be easily perturbed upon interaction with
S100A9, the differential CD spectrum of their equimolar
mixture was plotted, from which the contribution of the
S100A9 spectrum was subtracted. The ellipticity of the
minimum at 197 nm did not change in this differential
spectrum, but the amplitude of the peak with a minimum
at 220 nm was increased, indicating that a certain change
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Fig. 5 Amyloid co-aggregation and cytotoxicity of S100A9 and α-syn. a Normalized kinetic curves of amyloid formation monitored by ThT fluorescence
and fitted by sigmoidal function for 70 μM α-syn (in black), 70 μM S100A9 (blue), and both proteins taken at equimolar ratio (red). Experimental data
points are shown in gray. b Lag phase (dark bars) and midpoint of growth phase (light bars) of the amyloid formation kinetics derived from fitting.
Protein samples are indicated under the x-axis and in the same color coding as in a. c Growth rate constant derived from fitting. Protein samples are
indicated under the x-axis and in the same color coding as in a. Error bars represent SD. p≤ 0.05 is indicated by *. d–i AFM height images of oligomeric/
protofilament species of d S100A9, e α-syn, and f their equimolar mixture formed after 10 h incubation; amyloid fibrils of g S100A9, h α-syn, and i their
co-aggregates at equimolar ratio of both proteins formed after 60 h incubation. Scale bars equal to 500 nm in all images. j, k AFM cross-sections of
amyloid fibrils of S100A9 and α-syn, as shown by white cross-sections in g, h, respectively. l Viability of SH-SY5Y cells measured by WST-1 assay after 24 h
co-incubation with α-syn and S100A9 species. Viability of cells treated with PBS alone is shown by gray bar; cells treated with 10 μM α-syn, 10 μM
S100A9, or their equimolar mixture are shown by black, blue, and red bars, respectively. The durations of amyloid sample aggregation prior adding to cell
culture, i.e., 0, 10, and 60 h, are indicated under the x-axis by black, green, and red bars, respectively; the oligomeric and fibrillar sample time collections
are marked by red and green arrows, respectively, in the amyloid formation kinetics in a. Error bars represent SD of at least nine measurements. All
protein samples were incubated in PBS, pH 7.4 and 37 °C
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in secondary structure is induced in α-syn upon S100A9
binding (Fig. 6d).
In order to quantify interactions between these two
proteins, we have performed the titration of α-syn by
increasing concentrations of S100A9 using surface plas-
mon resonance technique. While α-syn was immobilized
on the surface of the Biacore chip, increasing concentra-
tions of S100A9 were injected in a step-wise manner.
S100A9 binding to α-syn was detected by an increase in
the response signal, corresponding to the increased mass
of bound material. The dissociation constant for α-syn
and S100A9 interaction calculated by fitting the titration
curve was ca. 5.0 ± 0.8 μM.
Discussion
Here, we have shown that S100A9 is abundant in the PD
brain tissues both intracellularly and in Lewy body
amyloid deposits (Figs. 1, 2, and 4). Importantly, S100A9
possesses dual properties as a pro-inflammatory mediator
and amyloidogenic protein [18, 19]. Chronic neuroinflam-
mation is one of the hallmarks of PD pathophysiology, as-
sociated with increased pro-inflammatory mediator levels
in the PD brain tissues [10–14]. Due to its inherent amy-
loidogenicity, S100A9 may play a more important role in
PD pathology than merely being one of the disease-related
pro-inflammatory mediators: it may contribute to the de-
velopment of the PD amyloid-neuroinflammatory cascade
a
b
c
d
e
Fig. 6 NMR, CD, and surface plasmon resonance studies of α-syn and S100A9 interactions. a 2D 1H,15N-HSQC spectra of 77 μM α-syn before (blue)
and after (red) titration with up to 2.5 mM S100A9 in 10 mM phosphate buffer, pH 7.4 and at 10 °C. b Ratios of α-syn amide crosspeak intensities
measured in the presence (I) and in the absence (I0) of S100A9, plotted as a function of α-syn amino acid residue numbers. c Far UV CD spectra of α-
syn (black) and S100A9 (blue), 6 μM of each protein in 10 mM phosphate buffer, pH 7.4 and 20 °C. d Far UV CD spectrum of 6 μM α-syn alone before
(black) and after addition of equimolar S100A9 (red), the signal of S100A9 was subtracted from the CD spectrum of the mixture. e Surface plasmon
resonance response upon binding of injected S100A9 to surface-immobilized α-syn plotted as a function of S100A9 concentration
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in a similar way as shown previously in Alzheimer’s dis-
ease [18]. Immunohistochemical analysis showed that
S100A9 is present in 20% of all α-syn-immunopositive
Lewy bodies in the PD substantia nigra and frontal lobe.
Within those bodies, S100A9 is clearly co-localized with
α-syn either within the same outer layer (Figs. 1 and 2) or
distributed throughout the whole Lewy body section
(Fig. 2). Lewy bodies were evenly spread throughout the
substantia nigra, which is typical for PD pathology. Lewy
bodies were also observed in the frontal lobe areas of PD
patients (Braak stages 4–6), though they were in smaller
quantities (Fig. 2g–j). Lewy bodies were not observed any-
where in the brain tissues of the controls (Fig. 3).
AFM imaging of Lewy bodies in the substantia nigra
enabled us to measure their dimensions more accurately.
Lewy bodies in the substantia nigra appeared to display
very regular structures, characterized by rather tight
margins for their outer and inner diameters and their an-
nuli thicknesses proportional to the diameters (Fig. 1). This
signifies that Lewy bodies were formed via common mech-
anisms. The fact that they have a dense core, as reported
previously [42], might be the underlying reason for the lack
of immunostaining in their central area. The immunopo-
sitive outer layer could be indicative of the lamellar
growth mechanism, which may be a diffusion-limited
process for the deposited protein and depend also on
the life span of the host cells, which provide the pro-
tein assembly environment.
The immunohistochemical analysis revealed that S100A9
and α-syn are present intracellularly both in the substantia
nigra and frontal lobe areas of PD patients (Figs. 2 and 4).
S100A9 was found to be predominantly expressed in neur-
onal cells, which is similar to the previous observations in
the Alzheimer’s disease brain tissues [18]. However, we
cannot exclude its presence in microglial cells. This indi-
cates that the pathogenic conditions associated with oxida-
tive stress and amyloid self-assembly in amyloid diseases
such as PD and Alzheimer’s disease may induce expression
of S100A9 in neurons [18]. Initially, S100A9 was discov-
ered in myeloid cells; however, its expression under cellular
stress conditions can be induced in various cell types
including epithelial cells, fibroblasts as well as neurons,
indicating that S100A9 may exert its functions in a pleth-
ora of cell types [43–45]. In the substantia nigra, S100A9
and α-syn were found to be co-localized in up to 77% of
neuronal cells. At the same time, Lewy neurites were
immunoreactive only with α-syn, but not S100A9 anti-
bodies (Fig. 2a, b), indicating that these proteins are not al-
ways present in the same cell regions.
Perturbation of the CD spectra of α-syn in the presence
of S100A9 indicated that S100A9 and α-syn interact with
each other, thereby causing additional secondary structure
formation of natively unfolded α-syn molecules (Fig. 6c, d).
The apparent dissociation constant of their interactions is
ca. 5 μM as determined in a surface plasmon resonance
technique (Fig. 6e). The α-syn HSQC spectrum recorded
in the presence of S100A9 shows a decrease of cross-peak
intensities, particularly for residues corresponding to the
C-terminal region of α-syn, suggesting the location of the
S100A9 binding site (Fig. 6a, b). It has been shown
previously that transient interactions between the α-syn
C-terminal and N-terminal or central NAC regions are
important in maintaining its natively unfolded structure,
thereby preventing α-syn aggregation and fibrillation [46].
Contacts between α-syn and S100A9, that perturb such
aggregation inhibiting self-interactions, could therefore
enhance α-syn aggregation.
Indeed, co-aggregation of α-syn and S100A9 occurs sig-
nificantly faster than amyloid formation of the individual
proteins (Fig. 5a). Interestingly, native S100A9 is more
prone to potentiate α-syn amyloid formation than its fi-
brils. Previously, similar effect of native S100A6, which is
structurally homologous to S100A9, was observed on the
amyloid fibrillation of superoxide dismutase-1 (SOD-1)
[47]. In addition to the removal of the amyloid inhibiting
interactions within α-syn primary structure, the faster
nucleation process of S100A9, characterized by shorter lag
phase than the lag phase of α-syn alone (Fig. 5a), may
provide seeding effect on α-syn amyloid growth nuclei. In-
deed, the amyloid formation of S100A9 was well described
by the Finke-Watzky model of nucleation-autocatalytic
growth with dominant nucleation phase, while there was
no evidence of the secondary nucleation pathways initiated
on S100A9 fibrillar surfaces [18, 20], which may be the rea-
son for the small cross-seeding effect of its fibrils on α-syn
fibrillation (i.e., inducing small but significant shortening of
α-syn fibrillation lag phase and growth midpoint as shown
in Additional file 2). At the same time, S100A9 fibrils are
characterized by highly hydrophobic surfaces as shown
previously [18, 20] and therefore, they may sequestrate
α-syn molecules from solution, effectively reducing its con-
centration, which manifested in decreased α-syn fibrillation
rate in their presence.
The co-aggregates of mixed S100A9 and α-syn, sampled
at the oligomer and fibrillar stages, are significantly larger
in size than the corresponding amyloid structures of the
individual proteins (Fig. 5d–i), and this correlates with a
reduction of S100A9 amyloid oligomer cytotoxicity
(Fig. 5l). As the amyloid oligomers of S100A9 are more
toxic than those of α-syn, S100A9 and α-syn
co-aggregation effectively rescues cells from S100A9 amyl-
oid cytotoxicity. Interestingly, similar effect has been ob-
served previously upon the co-aggregation of S100A9 and
Aβ1-40/Aβ1-42, respectively, when interactions with the
corresponding polypeptides also rescued S100A9 oligo-
mer cytotoxicity [18]. Due to the abundance of
S100A9 in neuronal tissues, S100A9 oligomers may
otherwise cause huge neuronal damage. This implies
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also that the co-aggregation of amyloidogenic poly-
peptides potentially could serve as a sink of danger-
ous amyloid species, removing them from active
circulation.
The abundance and inherent amyloidogenicity of
S100A9 raises the question if this protein can be a trig-
ger of pathological amyloid cascade in PD. Indeed,
S100A9 is present in the neuronal cells and Lewy bodies
in the substantia nigra, the region primarily affected by
disease, and in the PD frontal lobe areas, which are af-
fected by the disease at its later stages (Figs. 1, 2, and 4).
Moreover, S100A9 is present in neuronal cells and blood
vessels of aged patients without PD symptoms (Fig. 3).
We suggest here that sustained neuroinflammation pro-
moting the spread of amyloidogenic S100A9 in the brain
tissues can be a trigger of the amyloid cascade involving
α-syn and leading to PD development [11], similar to
the effect of S100A9 on Aβ aggregation in the Alzhei-
mer’s disease [18]. S100A9 could be a common denom-
inator in a broad variety of inflammation-dependent
amyloidoses, which may develop in various tissues and
organs of the human body from the brain to the aging
prostate, as we have shown previously [18, 48].
Conclusions
This is the first report on the co-aggregation of α-syn
and S100A9 both ex vivo and in vitro. Co-localized and
co-aggregated S100A9 and α-syn were found in Lewy
bodies and neuronal cells in the PD substantia nigra
and frontal lobe areas. In vitro, their co-aggregation
occurred significantly faster than self-assembly of indi-
vidual proteins, leading to the formation of larger
amyloid aggregates and mitigating the cytotoxicity of
S100A9 oligomers. The finding of S100A9 involvement
in PD may open a new avenue for therapeutic interven-
tions targeting S100A9 as a pro-inflammatory protein
and preventing its amyloid self-assembly in the brain
tissues.
Additional files
Additional file 1: Cross-seeding of α-syn amyloid formation by S100A9
amyloid fibrils. (A) Normalized kinetic curves of amyloid formation
monitored by ThT fluorescence and fitted by sigmoidal function for
70 μM α-syn (shown in black), in the presence of 5% (magenta) and
10% (cyan) of S100A9 fibrillar samples. Experimental data points are
shown in gray. (B) Lag phase (filled bars) and midpoint of growth phase
(striped bars) of the amyloid formation kinetics derived from fitting.
Protein samples are indicated under x-axis and in the same color
coding as in (A). (C) Growth rate constant derived from fitting. Protein
samples are indicated under x-axis and in the same color coding as in
(A). Error bars represent SD. p ≤ 0.05 is indicated by *. (PDF 104 kb)
Additional file 2: Statistical analysis of the effects of S100A9, α-syn and
mixed specimens on SH-SY5Y cellular viability presented in Fig. 5l. Cell
viability values were compared pair-wise by using two-sample t-test,
n ≥ 9. NS denotes non-significant difference, * − p ≤ 0.05 and ** − p ≤ 0.01.
(PDF 100 kb)
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